Akoya Biosciences (AKYA) shares soared 7.4% in the last trading session to close at $5.96. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 6.7% gain over the past four weeks.
The sudden rise in the stock price can be attributed to the positive investor expectations regarding the company's financial performance in the fourth quarter of 2023. Akoya generates revenues from the sale of its products and services. Product revenues include the sale of instruments, reagents and software. Per its preliminary fourth-quarter 2023 earnings press release, the company expects total revenues in the range of $25.5-26.5 million, marking a 20-25% increase compared to the $21.2 million recorded in the year-ago quarter.
This tissue analysis provider is expected to post quarterly loss of $0.27 per share in its upcoming report, which represents a year-over-year change of +46%. Revenues are expected to be $26.12 million, up 23.1% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Akoya, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on AKYA going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Akoya is a member of the Zacks Medical - Biomedical and Genetics industry. One other stock in the same industry, Avidity Biosciences, Inc. (RNA), finished the last trading session 5.8% higher at $12.32. RNA has returned 1.6% over the past month.
Avidity Biosciences, Inc.'s consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.54. Compared to the company's year-ago EPS, this represents a change of +38.6%. Avidity Biosciences, Inc. currently boasts a Zacks Rank of #3 (Hold).
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s credited with a “watershed medical breakthrough” and is developing a bustling pipeline of other projects that could make a world of difference for patients suffering from diseases involving the liver, lungs, and blood. This is a timely investment that you can catch while it emerges from its bear market lows.
It could rival or surpass other recent Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock And 4 Runners UpAkoya Biosciences, Inc. (AKYA) : Free Stock Analysis Report
Avidity Biosciences, Inc. (RNA) : Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
